

Clinical Trial Protocol

Iranian Registry of Clinical Trials

07 Aug 2026

The effect of hydro-alcoholic extract of *Portulaca Oleracea* L. (purslane) on Liver enzymes, Glycemic status and lipid profile in non-alcoholic fatty liver disease: a randomized, double-blind clinical trial.

Protocol summary

Study aim

The aim of this study was to evaluate the effect of portulaca oleracea (purslane) hydroalcoholic extract in patients with non-alcoholic fatty liver disease (NAFLD).

Design

A 12-week randomized, double-blinded, parallel clinical trial on 74 patients with NAFLD.

Settings and conduct

Patients are randomly divided into intervention and placebo groups (37 patients in each group). The study process is described for each patient and a written consent form is obtained from the patients. The degree of hepatic steatosis is determined using ultrasound once at the beginning and again at week 12 of the study. The 3-day of 24-hour dietary recall is taken at the beginning and end of the study. A diet for 10% weight loss will be provided to each patients individually by a nutritionist. Patients' compliance is monitored by telephone every 15 days. Fasting blood samples are taken from patients at the beginning and at end of the study. The study protocol has been approved by the ethics committee of Iran University of Medical Sciences.

Participants/Inclusion and exclusion criteria

Men and women with non-alcoholic fatty liver disease whose ALT is greater than 30 U / l and more than 19 U / L, respectively, and who do not have chronic liver disease, cardiovascular disease, hypertension, or kidney stones are eligible to participate in the study.

Intervention groups

Intervention group: one capsule containing 300 mg of purslane hydroalcoholic extract daily. Placebo Group: A capsule daily similar in appearance to drug capsules, filled with toasted powder.

Main outcome variables

Serum levels of ALT and AST are the main outcomes of the study. Other variables include fasting blood glucose, insulin, total cholesterol, triglycerides, HDL-C, LDL-C,

gamma glutamyl transferase, alkaline phosphatase, glutathione peroxidase, total bilirubin, adiponectin, NF-κB and expression of the NF-κB gene.

General information

Reason for update

1. Submission of information in the old version of IRCT 2. Creating some changes in the sample size after the approval of the Vice Chancellor for Research of Iran University of Medical Sciences 3. Correcting the secondary outcome variables

Acronym

IRCT registration information

IRCT registration number: **IRCT201701172709N44**
Registration date: **2017-04-10, 1396/01/21**
Registration timing: **prospective**

Last update: **2020-06-21, 1399/04/01**

Update count: **2**

Registration date

2017-04-10, 1396/01/21

Registrant information

Name

Farzad Shidfar

Name of organization / entity

Iran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 8862 2755

Email address

shidfar.f@iums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor for Research of Iran university of Medical

Expected recruitment start date

2017-06-22, 1396/04/01

Expected recruitment end date

2018-06-22, 1397/04/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of hydro-alcoholic extract of Portulaca Oleracea L. (purslane) on Liver enzymes, Glycemic status and lipid profile in non-alcoholic fatty liver disease: a randomized, double-blind clinical trial.

Public title

Effect of purslane extract on non-alcoholic fatty liver disease

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Being volunteer or Wishing to attend Age 18 years or older Alanine aminotransferase (ALT) greater than 19 IU/L for women and greater than 30 IU/L for men Evidence of fatty liver in ultrasonography with a score of 1 or more BMI: 20-40 kg/m2

Exclusion criteria:

Other acute or chronic hepatic disorders (hepatitis B or C) Biliary diseases Cancer Hypertension History of cardiovascular disease Nephrolithiasis (oxalate stones) or history of oxalate stones Consumption of omega-3 and vitamin E supplement Alcohol use Use of hepatotoxic medications during last month Changing medication dosage during the study Pregnancy Lactation Compliacne less than 80%

Age

From 18 years old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: 74

Randomization (investigator's opinion)

Randomized

Randomization description

Block randomization method has been used for randomization. Blocks of size 4 are generated using www.sealedenvelope.com. In order to conceal in the randomization process, unique codes have been used on the medicine boxes, which are produced by the software.

Blinding (investigator's opinion)

Double blinded

Blinding description

In order to apply concealment in the randomization process, unique codes will be used on the medicine boxes, and the desired code will also be produced by the software.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Iran University of Medical Sciences

Street address

Iran University of Medical Sciences, Shahid Hemmat Highway.

City

Tehran

Province

Tehran

Postal code

1449614535

Approval date

2017-02-22, 1395/12/04

Ethics committee reference number

IR.IUMS.REC 1395.95-04-27-9221324202

Health conditions studied

1

Description of health condition studied

Nonalcoholic fatty liver disease

ICD-10 code

K76.0

ICD-10 code description

Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description

Alanine aminotransferase (ALT)

Timepoint

At the begining and at the end of week 12

Method of measurement

Laboratory kit

2

Description

Aspartate aminotransferase (AST)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

Secondary outcomes

1

Description

Weight

Timepoint

At the beginning and at the end of week 12

Method of measurement

Seca scale

2

Description

Body mass index (BMI)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Calculation: weight (in kilograms) divided by the square of height (in meters)

3

Description

Waist circumference

Timepoint

At the beginning and at the end of week 12

Method of measurement

Non-stretchable measuring tape

4

Description

Liver steatosis

Timepoint

At the beginning and at the end of week 12

Method of measurement

Sonography

5

Description

Systolic blood pressure (SBP)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Sphygmomanometer

6

Description

Diastolic blood pressure (DBP)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Sphygmomanometer

7

Description

Total cholesterol

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

8

Description

Triglyceride (TG)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

9

Description

High density lipoprotein (HDL)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

10

Description

Low density lipoprotein (LDL)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

11

Description

Albumin (ALB)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

12

Description

Alkaline phosphatase (ALP)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

13

Description

Gamma glutamyl transferase (GGT)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

14

Description

Total bilirubin

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

15

Description

Fasting blood sugar (FBS)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit

16

Description

Insulin

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit (ELISA)

17

Description

Homeostatic model assessment of insulin resistance (HOMA-IR)

Timepoint

At the beginning and at the end of week 12

Method of measurement

Calculation: [fasting insulin (mU/L) * fasting blood glucose (mg/dl)]/405

18

Description

Glutathione peroxidase activity

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit (ELISA)

19

Description

Adiponectin

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit (ELISA)

20

Description

Serum NF-kB concentration

Timepoint

At the beginning and at the end of week 12

Method of measurement

Laboratory kit (ELISA)

21

Description

NF-kB gene expression

Timepoint

At the beginning and at the end of week 12

Method of measurement

Real Time RT-PCR

Intervention groups

1

Description

Intervention group: consumption of one capsule per day (containing 300 mg hydroethanolic extract of purslane) for 12 weeks

Category

Treatment - Other

2

Description

Control group: consumption of one placebo capsule for 12 weeks

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Rasoul akram Hospital

Full name of responsible person

Dr. Shahram Agah

Street address

Niayesh St., Sattarkhan Ave., Rasoul akram Hospital.

City

Tehran

Province

Tehran

Postal code

1445613131

Phone

+98 21 6435 1000

Email

hrmc@iums.ac.ir

Web page address

<https://hrmc.iums.ac.ir/>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Dr. Seyyed Abbas Motevallian, deputy head of Research and Technology, Iran University of Medical

Sci

Street address
Iran University of Medical Sciences, Shahid Hemmat Highway.

City
Tehran

Province
Tehran

Postal code
۱۴۴۹۶۱۴۵۳۵

Phone
+98 21 8670 2504

Fax

Email
research-m@iums.ac.ir

Web page address
<https://vcr.iums.ac.ir>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Iran University of Medical Sciences

Proportion provided by this source
100

Public or private sector
Public

Domestic or foreign origin
Domestic

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Dr. Farzad Shidfar

Position
Full Professor

Latest degree
Ph.D.

Other areas of specialty/work
Nutrition

Street address
Iran University of Medical Sciences, Shahid Hemmat Highway.

City
Tehran

Province
Tehran

Postal code
1449614535

Phone
00982188607941- 00982188607945

Fax
+98 21 8862 2707

Email
Shidfar.f@iums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Dr. Farzad Shidfar

Position
PhD of Nutrition

Latest degree
Ph.D.

Other areas of specialty/work
Nutrition

Street address
School of Health, Iran University of Medical Sciences, Shahid Hemmat Highway.

City
Tehran

Province
Tehran

Postal code
1449614535

Phone
+98 21 8860 7945

Fax
+98 21 8862 2707

Email
Farzadshidfar@yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity
Iran University of Medical Sciences

Full name of responsible person
Dr. Farzad Shidfar

Position
PhD of Nutrition, Full Professor

Latest degree
Ph.D.

Other areas of specialty/work
Nutrition

Street address
School of Health, Iran University of Medical Sciences, Shahid Hemmat Highway.

City
Tehran

Province
Tehran

Postal code
1449614535

Phone
+98 21 8860 7945

Fax
+98 21 8862 2707

Email

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Information on the main outcomes at the end of the study can be shared.

When the data will become available and for how

long

The access period will be 6 months after the publication of the results.

To whom data/document is available

The data from this study will only be available to researchers working at academic and scientific institutions.

Under which criteria data/document could be used

Six months after the publication of the articles of this project, upon request from the corresponding author and his agreement, the study data can be made available to researchers.

From where data/document is obtainable

Applicants can contact the corresponding author via email or the following postal address to receive the required data. Nutrition department, School of health, Iran University of Medical Sciences, Hemmat highway, Tehran Phon number:0098 21 8862 2755 E-mail: Farzadshidfar@yahoo.com

What processes are involved for a request to access data/document

Applicants will be able to access the data from the present study no later than one week by sending an email to the corresponding author.

Comments